Transfection

Viral Vector and Plasmid DNA Technologies and Global Market Analysis - A USD 7.1 Billion Market by 2028, Expansion of Biotechnological Applications Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Infectious Diseases, Genetics, Science, AAV, Transfection, QC, HSV, Acute lymphoblastic leukemia, Growth, Prevalence, Cell, Incidence, ALL, Tissue, DNA, Mortality, Virus, Cancer, Human, Infection, World Health Organization, Neoplasm, Immunization, Safety, WHO, Therapy, Inosine pranobex, USD, DSM-IV codes, Tisagenlecleucel, Vaccine

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.

Key Points: 
  • The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.
  • However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.
  • The global viral vector and plasmid DNA technologies market is segmented based on the product, application, and end-user.
  • Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors.

Agathos Biologics Launches Recombinant Adeno-Associated Virus Production Service Using Novel AE1-BHK Cell Line

Retrieved on: 
Wednesday, March 6, 2024
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Plasmid, ATCC, Multimedia, Sale, Transfection, Cell, Antibody, HEK293, Patent, Poster, Immortalised cell line, ATCC (company), AAV, Vaccine

Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.

Key Points: 
  • Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.
  • View the full release here: https://www.businesswire.com/news/home/20240305885603/en/
    The AE1-BHK cell line was developed by stable transfection of the BHK-21 (C-13) cell line (ATCC®, catalog number ATCC CCL-10™) with the adenoviral E1 gene.
  • “The launch of our custom rAAV service and the first sale of rAAV made using our AE1-BHK cell line is a significant milestone for the company,” said James Brown, CEO and co-founder of Agathos Biologics.
  • “To our knowledge, this is the first sale of rAAV produced using triple transfection in a cell line other than HEK293.

STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company

Retrieved on: 
Thursday, February 29, 2024
Health, Medical Devices, Health Technology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Acquisition, Cancer, Regenerative medicine, Multimedia, Stemcell Technologies, Cell, Electroporation, Interim, Patient, Electricity, Intellectual property, SQZ, Research, Transfection, Fine chemical

This transaction, which was approved by SQZ shareholders on February 29, 2024, marks another significant milestone for STEMCELL, Canada’s largest biotechnology company.

Key Points: 
  • This transaction, which was approved by SQZ shareholders on February 29, 2024, marks another significant milestone for STEMCELL, Canada’s largest biotechnology company.
  • (Photo: Business Wire)
    This transaction, which was approved by SQZ shareholders today, marks another significant milestone for STEMCELL, Canada’s largest biotechnology company.
  • In January 2024, STEMCELL purchased Propagenix Inc. , a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.
  • With this new agreement, STEMCELL will be able to exclusively commercialize these products for use in all markets, including clinical applications.

EurekaBio Completes $40 Million Series B+ Financing to Advance EuLV™ Lentiviral Vector Production System

Retrieved on: 
Thursday, March 7, 2024
Plasmid, Investment, Growth, Transfection, Series, LVV, CGT, Patient, AAV, Vaccine

SHENZHEN, China, March 7, 2024 /PRNewswire/ -- Shenzhen Eureka Biotechnology Co., Limited (EurekaBio), a leading upstream supplier in the cell and gene therapy field, announced the completion of its Series B+ financing, exceeding $40 million. The financing was led by YUEXIU INDUSTRIAL FUND, with participation from numerous well-known Chinese funds, as well as follow-on investments from U.S. funds.

Key Points: 
  • EurekaBio's core innovation lies in the EuLV™ Lentiviral Vector Production System, a cutting-edge technology that transforms the large-scale production of lentiviral vectors using stable cell lines and a serum-free suspension system.
  • In contrast to traditional transient transfection production methods, the EuLV™ Lentiviral Vector Production System eliminates the necessity for plasmids, resulting in cost savings related to plasmid production and streamlining the overall production process.
  • Moreover, the EuLV™ system adopts a high-density suspension culture, which substantially increases unit titer levels, reduces production batches and associated costs and meets the requirements of large-scale lentiviral vector production.
  • The EuLV™ system presents a next-generation solution for lentiviral vector production to power cell and gene therapies, and is also well positioned for global adoption.

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

Retrieved on: 
Thursday, February 22, 2024
Iodine, NSCLC, Acquisition, Roche, Rigel, FDA, Food, RET, Growth, Sale, Transfection, Blueprint, Lung cancer, Hematology, Patient, Pharmaceutical industry

GAVRETO generated ~$28M in U.S. net product sales in 2023

Key Points: 
  • GAVRETO generated ~$28M in U.S. net product sales in 2023
    SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO® (pralsetinib) from Blueprint Medicines Corporation ("Blueprint").
  • "NSCLC is the most common type of lung cancer in the U.S. with RET fusions representing 1-2% of the patient population.
  • Rigel expects to complete the transition of the asset and start recognizing product sales in the third quarter of 2024.
  • Rigel will provide additional details on this transaction at its upcoming quarterly earnings call in early March.

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Retrieved on: 
Tuesday, January 30, 2024
Partnership, Cell engineering, LBL, Orphan drug, Expert, NK, Patient, Transfection, Adolescence, NCT, MBA, Food, Cancer, CD7, Doctor of Philosophy, SPL, Pharmaceutical industry

Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • Wugen is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.
  • The company’s investigational cell therapies originate from healthy donors and are further engineered to enhance their function of eliminating cancer cells.
  • Wugen is MaxCyte’s 26th clinical/commercial partnership overall, each of which generates pre-commercial milestone revenue, the vast majority of which includes sales-based payments.

EQS-News: Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028

Retrieved on: 
Tuesday, January 30, 2024
CO2, Patient, Deleveraging, Forecasting, Research, Sartorius, Face, Electricity, Novasep, Public expenditure, Acquisition, Sartorius AG, Acceleration, Transfection, Weakness, Vaccine, News, Growth

Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)

Key Points: 
  • Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • Sales revenue in the Americas region was down 14.9 percent and accounted for around 38 percent of the Group total.
  • In the Asia | Pacific region, in particular, the pronounced weakness of the market in China had a significant impact, with sales revenue down 22.1 percent.
  • Sartorius intends to continue its profitable growth path in the long term and expects to grow faster than the market.

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Retrieved on: 
Tuesday, January 23, 2024
ASX, Neoplasm, Patient, Precision, Partnership, Imugene, Cancer, Workflow, GMP, CD19, IMU, Cell engineering, SPL, Bone marrow, Transfection, Immune system, Pharmaceutical industry

Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
  • Imugene, which has offices in the United States and Australia, is focused on developing transformative cancer medicines to improve patients’ lives.
  • Imugene is MaxCyte’s 25th SPL overall, which generates pre-commercial milestone revenue, the vast majority of which includes post-commercial revenue.

Calibre Scientific Acquires RUWAG, a Swiss Provider of Diagnostics and Life Sciences Products and Services

Retrieved on: 
Monday, January 22, 2024
University, Hospital, History, Infection, Acquisition, Autoimmunity, Transfection, Gastroenterology, Cell, Microbiology

LOS ANGELES, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of RUWAG Handels AG (“RUWAG” or the “Company”), a provider of diagnostics and life sciences products and services, selling to hospitals, private labs, universities and pharmaceutical companies in Switzerland.

Key Points: 
  • LOS ANGELES, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of RUWAG Handels AG (“RUWAG” or the “Company”), a provider of diagnostics and life sciences products and services, selling to hospitals, private labs, universities and pharmaceutical companies in Switzerland.
  • This strategic acquisition highlights Calibre Scientific's dedication to broadening its range of products and services for customers within the DACH region.
  • The Company also provides life sciences products including transfection, cells, media, test kits, gene expression systems and endotoxin testing.
  • The RUWAG acquisition strengthens Calibre Scientific’s growing platform in Switzerland, a dynamic market for diagnostics and life sciences products given its prominent pharmaceutical industry.

Asimov launches LV Edge Packaging System to optimize lentivirus production

Retrieved on: 
Monday, January 29, 2024
Kernel, Synthetic biology, DNA, GMP, Risk, Transgene, Therapy, Transfection, CAD, Plasmid, Vaccine

BOSTON, Jan. 29, 2024 /PRNewswire/ -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.

Key Points: 
  • BOSTON, Jan. 29, 2024 /PRNewswire/ -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.
  • By removing the need to transiently transfect three out of the four GMP plasmids, the LV Edge Packaging System reduces manufacturing cost and supply chain risk without compromising speed to market.
  • The LV Edge Packaging System achieves high harvest titers of over 1E8 TU/mL across multiple chimeric antigen receptor (CAR) transgenes and enables tuneable transgene expression in the transduced cell.
  • For more information on the LV Edge Packaging System, please visit: www.asimov.com/ LV